ClinicalTrials.gg
CompletedNCT02852681Updated Aug 2, 2016

Effect of Food on the Bioavailability of 15 mg Estetrol/3 mg Drospirenone Tablets in Healthy Female Volunteers

A Phase 1 interventional study of 15 mg E4/3 mg DRSP in Contraception, sponsored by Estetra. Completed. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-02.

Sponsored by Estetra · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

This single-center, open-label, randomized, balanced, single-dose, two-treatment, two-period, two-sequence crossover study was conducted under medical supervision in 28 healthy female volunteers.

Read the detailed description

Food effect bioavailability studies are usually conducted for new drugs and drug products to assess the effect of food on the rate and extent of absorption of a drug when the drug product is administered shortly after a meal (fed conditions), as compared to administration under fasting conditions. Therefore, this study was designed to characterize the effect of a high fat meal on the bioavailability of E4 and DRSP after administration of a single tablet containing 15 mg E4 and 3 mg DRSP.

All subjects entered the study site at least 12 hours before each dosing and fasted for at least 10 hours prior to each dose.

All subjects were to receive both Treatment A (Reference; a single 15 mg E4/3 mg DRSP tablet without food (fasted)) and Treatment B (Test; a single 15 mg E4/3 mg DRSP tablet with food (fed)) either at the first treatment period (Period 1) or the second treatment period (Period 2). Approximately half of the subjects were randomized to receive either Treatment A followed by Treatment B (Sequence AB), or Treatment B followed by Treatment A (Sequence BA).

02

Conditions studied

  • Contraception
03

In context

Lead sponsor

Estetra is the lead sponsor of 15 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overtly healthy females.
  • Between the ages of 18 and 45 years, inclusive.
  • Non-smokers who have not used tobacco or nicotine in any form during the 3 months prior to the screening visit.
  • Between the (BMI) of 18 and 30 kg/m2, inclusive, and body weight 45kg.
  • Negative serum pregnancy test results at screening and negative urine pregnancy test results before dosing.
  • Willing to use double-barrier methods of non-hormonal during the entire study period.

Exclusion criteria

Exclusion Criteria:

Potential study subjects were not entered into and/or may have been discontinued from the study if any of the following applied:

  • Use of

    • progestogen-only methods [e.g., minipill, implant or, intrauterine system (IUS)] during the last 3 months prior to the first dose or,
    • depot progestogen preparations or an injectable hormonal method of contraception (e.g., Depo-Provera) during the last 6 months prior to the first dose.
  • Use (within 28 days prior to first dose) of other hormonal contraceptive method.
  • Use of

    • any prescription drugs (except thyroid hormone supplements) or herbal supplements acting on functions (e.g., St. John's Wort), within 28 days prior to the first dose until study completion,
    • any over-the-counter (OTC) medication (including paracetamol) or dietary supplements (vitamins included) within 14 days prior to the first study dose until study completion.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Other
    15 mg E4/3 mg DRSP without food

    Treatment A (Reference): a single 15 mg E4/3 mg DRSP tablet without food (fasted).

    Drug: 15 mg E4/3 mg DRSP

  • Other
    15 mg E4l/3 mg DRSP with food

    Treatment B (Test): a single 15 mg E4/3 mg DRSP tablet with food (fed)

    Drug: 15 mg E4/3 mg DRSP

Interventions

  • Drug15 mg E4/3 mg DRSP

    Drug pages: Estetrol · Drospirenone

    All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (Sequence AB), or Treatment B followed by Treatment A (Sequence BA)

    Also known as: 15 mg Estetrol/3 mg Drospirenone

06

What researchers measure

Primary outcomes

  1. Maximum concentration (Cmax) of estetrol in plasma

    PK sampling

    Time frame: From day 1 to 4 during both period 1 and period 2

  2. Cmax of drospirenone in plasma

    PK sampling

    Time frame: From day 1 to 4 during both period 1 and period 2

  3. Area under the plasma concentration versus time curve from time 0 to the last determined concentration (AUC0-tdlc) of estetrol

    Time frame: From day 1 to 4 during both period 1 and period 2

  4. AUC0-tdlc of drospirenone

    Time frame: From day 1 to 4 during both period 1 and period 2

  5. AUC0-inf of estetrol

    PK sampling

    Time frame: Day 1 to 4 during both period 1 and period 2

  6. AUC0-inf of drospirenone

    PK sampling

    Time frame: Day 1 to 4 during both period 1 and period 2

Secondary outcomes

  1. Number of subjects with adverse events as a measure of safety and tolerability

    Time frame: From up to day 28 before randomization (28 day screening/run-in period) to day 4 of the Period 2

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2015, a primary completion of Oct 2015 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2016
First posted
Aug 2, 2016
Start
Aug 2015
Primary completionActual
Oct 2015
CompletionActual
Apr 2016
Last update
Aug 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02852681
Lead sponsor
Estetra
Responsible party
Sponsor
First posted
Aug 2, 2016
Start date
Aug 2015
Primary completion
Oct 2015
Completion
Apr 2016
Last update
Aug 2, 2016

Study contacts

Dobrin Sviranov, MD
principal investigator · Comac Medical

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estetrol · Drospirenone

Start the discussion